Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement

Scandinavian Journal of Rheumatology

Volumn 33, Issue 5, 2004, Pages 323-326

  Rejon E ^a   Gimenez M D ^a   Mayordomo, L ^a   Rodriguez S ^a   Gonzalez M P ^a   Marenco, J L ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HUMAN; MORNING STIFFNESS; PAIN; PHYSICIAN; PRIORITY JOURNAL; SIDE EFFECT; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFLAMMATION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING;

EID: 7044235175     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740310004720     Document Type: Article

References (27)

1. Van der Linden S, Van der Heijde D. Clinical and epidemiologic aspects of ankylosing spondylitis and spondyloarthropathies. Curr Opin Rheumatol 1996;8:269-74.
2. Dougados M, Van der Linden S, Jhulin R, Huitfeldt B, Amor B, Calin A, et al. [The European Spondyloarthropathy Study Group]. Preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991;34:1218-27.
3. Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000;29:160-2.
4. Altan L, Bingol U, Karakoc Y, Aydiner S, Yurtkuran M, Yurtkuran M. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001;30:255-9.
5. Marshall RW, Kirwan JR. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001;30:313-4.
6. Leirisalo-Repo M. Therapeutic aspects of spondyloarthropathies - a review. Scand J Rheumatol 1998;27:323-8.
7. Amor B, Dougados M, Khan MA. Management of refractary ankylosing spondylitis and related spondylarthropathies. Rheum Dis Clin N Am 1995;21:117-28.
8. Dinarello C. Proinflammatory cytokines. Chest 2000;118:503-8.
9. Beutler BA. The role of tumour necrosis factor in health and disease. J Rheumatol 1999;26 Suppl. 57:16-21.
10. Ksontini R, Mackay SLD, Moldawer LL. Revisiting the role of tumour necrosis factor α and the response to surgical injury and inflammation. Arch Surg 1998;133:558-67.
11. Knight DM, Trinh H, Le J, Siegel S, Shealy D, Mc Donough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
12. Van Deventer SJH. Targetting TNF-α as a key cytokine in the inflammatory processes of Crohn's disease - the mechanisms of action of infliximab. Alim Pharmacol Ther 1999;13 Suppl. 4:3-8.
13. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
14. Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld F, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
15. Braun J, Sieper J. Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies. Ann Rheum Dis 2000;59:404-7.
16. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000;356:1821-2.
17. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthrophaty: an open pilot study. Ann Rheum Dis 2000;59:428-33.
18. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
19. Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumour necrosis factor therapy. Curr Opin Rheumatol 2001;13:245-9.
20. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short-term treatment of severe undifferentiated spondyloarthropathy with the anti-tumour necrosis factor α monoclonal antibody infliximab. J Rheumatol 2002;29:118-22.
21. Van den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, Veys EM. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
22. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open label study. Rheumatol 2002;41:1280-5.
23. Braun J, Baraliakos X, Golder W, Listing J, Brandt J, Rudwaleit M, et al. Magnetic Resonance Imaging Examinations of the Spine in patients with Ankylosing Spondylitis before and After Successful therapy with Infliximab. Evaluation of a New Scoring System. Arthritis Rheum. 2003;48:1126-36.
24. D'Agostino MA, Breban M, Said-Nahal R, Dougados M. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum. 2002;46:840-1, author reply 841-3.
25. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
26. Garret S, Jenknison T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 1994;21:2286-91.
27. Calin A, Garret S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional hability in ankylosing spondylitis: the Bath ankylosing spondylitis functional index. J Rheumatol 1994;21:2281-5.